[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-amyloidosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-amyloidosis":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,36,0,25,[9,41,63,93,121,145,167,192,213,235,262,288,310,333,359,383,406,439,462,487,516,539,557,577,603],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100642081","prevalence-of-cardiac-thrombi-in-cardiac-amyloidosis-100642081",false,"NCT07648303","Prevalence of Cardiac Thrombi in Cardiac Amyloidosis","CATICA","Inclusion Criteria:\n\n* Individuals with a diagnosis of cardiac amyloidosis (AL diagnosed by echocardiography and\u002For MRI combined with histological evidence; or ATTR diagnosed in the presence of typical cardiac abnormalities on echocardiography and\u002For MRI with cardiac hyperintensity)\n* Individuals who have had at least one consultation related to their cardiac amyloidosis at the Dijon University Hospital during the year prior to enrollment\n* Adults\n\nExclusion Criteria:\n\n* Individuals with an estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m²\n* Anyone with a known allergy to iodinated contrast agents\n* Overt thyrotoxicosis\n* Uncontrolled asthma\n* Individuals with a known history of cardiac thrombus\n* Individuals with a history of percutaneous or surgical closure of the left atrial appendage\n* Individuals not enrolled in or not eligible for a social security program\n* Individuals under legal guardianship\n* Individuals under conservatorship\n* Pregnant or breastfeeding women","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cardiac amyloidosis (CA) is an infiltrative disease characterized by deposits of amyloid proteins of genetic or acquired origin (often in elderly patients), leading to heart failure and arrhythmias. More than 98% of currently diagnosed cases of cardiac amyloidosis result from fibrils composed of monoclonal immunoglobulin light chains (AL) or transthyretin (ATTR), in its hereditary (ATTRv) or acquired (ATTRwt) form.\n\nIts prevalence is rising sharply due to an aging population and improved diagnostic techniques. Atrial fibrillation is responsible, in particular, for heart failure, arrhythmias, conduction disorders, and ischemic strokes, and is associated with significant morbidity and mortality. These patients have a much higher-than-normal risk of stroke because they are in a procoagulant state in the left atrium, even in the absence of atrial fibrillation. Intracardiac thrombi (ICTs) are present in 28% of patients with AC requiring cardioversion, compared with 2.5% of patients without AC, 50% of whom are on anticoagulants.\n\nIt has also been shown that the CHA2DS2-VASc score is not effective in predicting thromboembolic risk, and that direct oral anticoagulants (DOACs) are as effective as vitamin K antagonists (VKAs) in preventing embolisms.\n\nThe prevalence and factors associated with the development of intracardiac thrombi in patients with cardiac amyloidosis are unknown, as the available retrospective studies focused only on selected high-risk patients. Furthermore, tafamidis is now available to stabilize the course of cardiac amyloidosis and improve prognosis, but its effect on thromboembolic risk remains unknown.",[27],"Cardiac Amyloidosis","NOT_YET_RECRUITING","2026-06-15",{"date":31,"type":32},"2026-06-16","ACTUAL",{"date":34,"type":21},"2026-07",{"date":36,"type":21},"2028-07",{"name":38,"class":39},"Centre Hospitalier Universitaire Dijon","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":40},"100446840","pathway-rct-preventing-admission-to-hospital-with-attr-cardiomyopathy-100446840","NCT05098665","PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY","PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY Using Remote Cardiac Telemonitoring","PATHWAY-RCT","Inclusion Criteria:\n\n1. Adults aged ≥18 at the date of signing informed consent which is defined as the beginning of the Screening Period.\n2. An established diagnosis of ATTR cardiomyopathy as defined by protocol.\n3. Ability to provide written, personally signed and dated informed consent to participate in the study, in accordance with the ICH Good Clinical Practice (GCP) Guideline E6 (R2) (2016) and applicable regulations, before completing any study-related procedures.\n4. An understanding, ability, and willingness to fully comply with study procedures and restrictions.\n5. Currently a patient at a study site (NAC).\n\nExclusion Criteria:\n\n1. An inability to have or use BodyTrace device scales at usual residence (for example no mobile network cellular signal)\n2. On dialysis or end-stage renal failure (eGFR \\\u003C25mL\u002Fmin)\n3. Serum albumin \\\u003C20g\u002FdL or other non-hypervolaemia cause of tissue oedema (e.g. protein-losing enteropathy, nephrotic syndrome)\n4. Use of greater than 2 oral diuretics (e.g. on maximum oral diuretic therapy)",{"count":50,"type":21},320,[24],"Cardiac amyloidosis is a condition where the heart muscle, amongst other tissues, is infiltrated by the abnormal build-up of proteins called amyloid. This stiffens and thickens the heart muscle over time which makes it less efficient and puts further stress and strain on the other chambers of the heart, leading to heart failure. The commonest form, that affects predominantly the elderly, is called 'wild-type' ATTR amyloid (TTR is the protein that accumulates). In this condition a patient has a 60% chance of admission to hospital each year after diagnosis. There is no current treatment for ATTR amyloid other than using water tablets to reduce excess fluid and prevent more serious fluid build up in lungs and other tissues. Increasing body weight is the most reliable clinical sign of this fluid build up.\n\nTele-monitoring is the practice of monitoring patients from a distance and has been shown to reduce heart failure admissions and death in patients with heart failure from any cause. Due to reduced access to primary and secondary care during COVID-19 the investigators instigated tele-monitoring of heart failure in ATTR amyloid patients. This appeared to be an effective intervention in the pilot study. The investigators propose to monitor the weight of patients with cardiac amyloidosis at home and intervene where a build up of fluid is observed by telephone discussion with a doctor. The investigators propose to evidence this in a prospective clinical trial. The investigators will evaluate the effect fairly by comparing tele-monitoring with usual care.",[27],"RECRUITING",{"date":31,"type":32},{"date":57,"type":32},"2025-01-01",{"date":59,"type":21},"2027-12",{"name":61,"class":62},"Richmond Research Institute","INDUSTRY",{"id":64,"slug":65,"hasResults":12,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100633682","ai-based-echocardiography-for-detection-of-cardiac-amyloidosis-100633682","NCT07529860","AI-based Echocardiography for Detection of Cardiac Amyloidosis","AI-based Echocardiography for Detection of Cardiac Amyloidosis in Patients Undergoing Transthoracic Echocardiography With Left Ventricular Hypertrophy","ORCHESTRA","Inclusion Criteria:\n\n* Patients 18 years old or older\n* Left ventricular hypertrophy defined by a wall thickness of at least 12 mm\n* Echocardiographic red flags of suspected cardiac amyloidosis\n* Informed consent signed\n\nExclusion Criteria:\n\n* Patients with poor echocardiographic acoustic window to allow proper analysis of the data\n* Patients with known cardiac amyloidosis.","95 Years",{"count":20,"type":21},[24],"Cardiac amyloidosis is characterized by deposition of misfolded protein in the myocardium causing mainly heart failure symptoms with preserved left ventricular ejection fraction. There are also specific clinical (bilateral carpal tunnel syndrome, polyneuropathy, skin bruising, ruptured biceps tendon…), biomarkers (disproportionally elevated NT-proBNP to the degree of heart failure, persistent elevated troponin, proteinuria..), electrocardiographic (reduced voltage of QRS, atrial fibrillation..) and echocardiographic features (concentric left ventricular hypertrophy, dilated atria, reduced global longitudinal strain with typical pattern of apical sparing, diastolic dysfunction…). Early diagnosis of the disease is crucial to identify patients that may benefit from appropriate treatment. Suspected cardiac amyloidosis on echocardiography or on cardiac magnetic resonance needs to prompt the request of serum free-light chain quantification and serum and urine immunofixation as well as single photon emission computed tomography (SPECT) using bone radiotracers. Echocardiography is the imaging technique of first choice to evaluate patients with dyspnea complaints and suspected heart failure as well as other pathologies. Echocardiography is a technique of first choice to evaluate patients with cardiovascular risk factors such as arterial hypertension and diabetes and many of those patients may have echocardiographic features that can be observed in early phases of cardiac amyloidosis. Currently, identification of patients with cardiac amyloidosis with available echocardiographic tools remains challenging. However, novel artificial intelligence (AI)-based algorithms applied to echocardiographic images for analysis may help the cardiologists in the identification of early phase of cardiac amyloidosis. Early diagnosis of cardiac amyloidosis is key to implement effective therapies that have demonstrated to improve survival. Several studies have demonstrated the accuracy of AI-based algorithms applied to echocardiography for the diagnosis of cardiac amyloidosis. The hypothesis of the present prospective study is to evaluate the accuracy of the AI-based algorithm to identify patients with echocardiographic findings suggestive of cardiac ATTR amyloidosis using as ground truth the subsequent analysis with imaging techniques that permit its diagnosis such as 99mTc-pyrophosphate (PYP) SPECT and cardiac magnetic resonance as well as hematologic tests. If needed, histological confirmation on cardiac or extracardiac tissue could be performed, as recommended by recent consensus document from the Heart Failure Association of the European Society of Cardiology.\n\nIn addition, this study will help to answer the true prevalence of ATTR cardiac amyloidosis among patients referred to transthoracic echocardiography that present red flags for ATTR cardiac amyloidosis. The AI-based algorithm is the software Us2.ai which has been used in other populations for this purpose, as previously published.",[27,76,77],"Heart Failure With Preserved Ejection Fraction (HFPEF)","Left Ventricular Hypertrophy",[79,80,81,82,83],"artifical intelligence","echocardiography","strain","cardiac amyloidosis","left ventricular hypertrophy","2026-06-10",{"date":86,"type":32},"2026-06-12",{"date":88,"type":21},"2026-07-01",{"date":90,"type":21},"2028-10",{"name":92,"class":39},"Germans Trias i Pujol Hospital",{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":17,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":120},"100518735","analysis-of-lumbar-spine-stenosis-specimens-for-identification-of-transthyretin-cardiac-amyloidosis-100518735","NCT06034405","Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis","Inclusion Criteria:\n\n1. Clinically indicated spinal decompressive surgery within 20 years prior to enrollment.\n2. Age ≥50 years at the time of the surgery.\n3. Able to understand and sign the informed consent document after the nature of the study has been fully explained.\n\nExclusion Criteria:\n\nThe presence of any of the following excludes eligibility for enrollment in this study:\n\n1. Confirmed primary amyloidosis (AL) or secondary amyloidosis (AA).\n2. Known TTR amyloidosis.\n3. Other reason that would make the subject inappropriate for entry into this study.",true,"50 Years",{"count":102,"type":21},1663,"OBSERVATIONAL","Primary objective:\n\nTo identify older adults with transthyretin cardiac amyloidosis (ATTR-CA) early in the course of the illness, at a time when disease modifying therapies are most effective.\n\nThe specific aims of this epidemiologic investigation include:\n\n1. To identify subjects with previous lumbar spinal stenosis (LSS) Surgery who have evidence of transthyretin (TTR) amyloid deposits in spinal specimens and could be at risk for ATTR cardiac amyloidosis.\n2. To evaluate for ATTR-CA among those with localized TTR in the spinal tissue.\n\nThe study will also explore the following:\n\n1. The prevalence of amyloid in lumbar spinal stenosis specimens by Congo Red staining.\n2. The prevalence of TTR deposits among subjects with amyloid as determined by mass spectrometry.\n3. Evaluation of a novel artificial intelligence technique for that can identify amyloid histologically with standard H\\&E staining.\n4. Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in subject's spine by myocardial uptake of technetium pyrophosphate scan (Tc99-PYP).",[106,27,107,108,109,110],"Lumbar Spinal Stenosis","ATTR Amyloidosis Wild Type","ATTR Gene Mutation","ATTRV122I Amyloidosis","Cardiomyopathy, Hypertrophic","2026-06-02",{"date":113,"type":32},"2026-06-04",{"date":115,"type":32},"2023-09-19",{"date":117,"type":21},"2028-05",{"name":119,"class":39},"Columbia University",6,{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":17,"minAge":129,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100576830","phase-1-test-retest-study-with-18ffbb-in-cardiac-amyloidosis-100576830","NCT06790394","Test-retest Study With [18F]FBB in Cardiac Amyloidosis","A Test-retest Study to Evaluate the Reproducibility of [18F]Florbetaben PET Imaging in Patients With Cardiac Amyloidosis and Control Patients","CATI","Inclusion Criteria:\n\n* Inclusion criteria (for all subjects):\n\n  * Males and females aged ≥40 years\n  * Able to understand, sign, and date written informed consent\n  * Written informed consent must be obtained before any assessment is performed\n  * Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or post-menopausal for at least 1 year (no menses for 12 months without an alternative medical cause). If they are of child-bearing potential, they must commit to use of a highly effective contraceptive measure for one week after the PET scan (including combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner or sexual abstinence)\n  * Male subjects and their partners of childbearing potential must commit to the use of a highly effective method of contraception for a minimum of 90 days following each PET scan (including, for female partners of childbearing potential, combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, male subjects with vasectomy or sexual abstinence)\n  * Male subjects must commit to not donate sperm for a minimum of 90 days after the PET scan\n  * Medications taken for treatment of multiple myeloma or chronic diseases of the heart or tafamides treatment are maintained on a stable dosage regimen.\n  * Patients on stable coagulation, if arterial blood sampling isperformed.\n* Inclusion criteria for AL-CA and ATTR-CA patients:\n\n  • Patients with a clinical diagnosis of cardiac AL amyloidosis or cardiac ATTR diagnosis according to diagnostic criteria\n* Inclusion criteria for control patients:\n\nThe control subjects must meet one of the following criteria:\n\n* Patients without heart failure and no suspicion of cardiac amyloidosis OR\n* Patients with impaired heart function but cardiac amyloidosis ruled out by echocardiography, CMR or cardiac biopsy OR\n* Patients with known plasma cell dyscrasia (MGUS, multiple myeloma) but no clinical signs of cardiac amyloidosis detected by echocardiography or CMR\n\nExclusion Criteria:\n\n* Subject has received, in the last 3 months, or currently receives amyloid targeting monoclonal antibody therapy.\n* Any known allergic reactions or hypersensitivity towards any compound of the study drug\n* Hemoglobin value \\\u003C 10 g\u002FdL\n* Severe hepatic impairment (AST or ALT \\>5 x ULN; bilirubin \\>3 x ULN)\n* Subject receives hemodialysis or peritoneal dialysis\n* Inability to lay flat for up to 60 min\n* Pregnant, lactating or breastfeeding\n* Unwilling and\u002For unable to cooperate with study procedures\n* Having received a PET scan within one week before the 18F\\]florbetaben PET scan\n* For patients were arterial sampling isperformed: Subject has a contraindication to arterial cannulation, including but not limited to allergy to local anesthetics, peripheral vascular disease, Raynaud's phenomenon as determined by abnormal Allen's test or abnormal coagulation profile at screening.","40 Years",{"count":131,"type":21},15,[133],"PHASE1","This study is an open-label study to evaluate and characterize test-retest reliability of \\[18F\\]florbetaben PET in subjects with AL-CA and ATTR-CA compared to non-CA subjects. Quantification of the \\[18F\\]florbetaben parameters related to the deposition of amyloid in the heart (such as Myocardial Tracer Retention (MTR) or Retention Index (RI)), and the variability in these parameters after repeated imaging will be evaluated. Measurement of blood metabolites and comparison of invasive with non-invasive quantification of \\[18F\\]florbetaben uptake in the heart will be performed.",[27],"2026-05-29",{"date":111,"type":32},{"date":139,"type":32},"2025-10-21",{"date":141,"type":21},"2026-09",{"name":143,"class":62},"Lantheus Germany GmbH",2,{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":71,"enrollmentInfo":153,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":4},"100638746","fast-cardiac-bone-spect-czt-in-transthyretin-cardiac-amyloidosis-100638746","NCT07605741","Fast Cardiac Bone SPECT-CZT in Transthyretin Cardiac Amyloidosis","Fast Cardiac Bone 360° SPECT-CZT Accurately Reproduces Planar Perugini ≥ 2 Classification With High Reproducibility in Transthyretin Cardiac Amyloidosis","PeakAmyL","Inclusion Criteria:\n\n* Patients who were routinely referred for bone scintigraphy for suspected transthyretin cardiac amyloidosis (ATTR-CA) between April 2024 and April 2025.\n\nExclusion Criteria:\n\n* Patients who object to the use of their data",{"count":20,"type":21},"Transthyretin cardiac amyloidosis (ATTR-CA) is traditionally diagnosed using planar bone scintigraphy with a Perugini visual score ≥ 2. Fast cardiac CZT-SPECT will be evaluated for its ability to reproduce this classification and provide reproducible quantitative myocardial uptake metrics.",[27],[157],"Cardiac amyloidosis, Bone scans, CZT, SPECT-CT, Perugini","2026-05-18",{"date":160,"type":32},"2026-05-26",{"date":162,"type":21},"2026-05-30",{"date":164,"type":21},"2026-07-30",{"name":166,"class":39},"Central Hospital, Nancy, France",{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":4},"100586901","retrospective-identification-of-scintigraphic-cardiac-amyloidosis-risca-100586901","NCT06921408","Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA)","Retrospective Identification of Scintigraphic Cardiac Amyloidosis Using Deep Learning-based Model","RISCA","Inclusion Criteria:\n\n* Adults (≥ 18 years)\n* Patients who underwent bone scintigraphy with 99mTc-HMDP\u002FDPD\u002FPYP for any indication\n* Incidental cardiac uptake (Perugini grade ≥2) confirmed by a nuclear medicine specialist\n\nExclusion Criteria:\n\n* Patients under legal protection\n* Patients refusing the reuse of their data after individual information",{"count":176,"type":21},57,"This study aims to determine the positive predictive value of incidental cardiac uptake on bone scintigraphy for diagnosing transthyretin cardiac amyloidosis, in patients who underwent scintigraphy for reasons other than suspected amyloidosis. The study is an observational, descriptive, multicenter, national study using retrospective data from routine care. Patients with incidental cardiac uptake will be recalled for further diagnostic assessment.",[27,179],"Transthyretin Amyloidosis",[27,181,182],"Bone Scintigraphy","Deep learning","2026-05-14",{"date":185,"type":32},"2026-05-15",{"date":187,"type":21},"2026-09-01",{"date":189,"type":21},"2027-12-01",{"name":191,"class":39},"University Hospital, Lille",{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":40},"100637987","elevated-rate-pacing-of-cardiac-amyloidosis-100637987","NCT07583823","Elevated Rate Pacing of Cardiac Amyloidosis","Inclusion Criteria:\n\n* Adults 18 and older\n* Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: \"2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee\n* Implanted Cardiac Pacemaker (+\u002F- Defibrillator)\n* Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation\n* Non-dilated left ventricle by echocardiography\n* Ability to provide written consent\n* English Speaking\n\nExclusion Criteria:\n\n* Paced QRS duration of \\>150 ms (indicator for pacing mediated dyssynchrony)\n* Dilated left ventricle",{"count":199,"type":21},10,[24],"This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.",[27,203],"Pacemaker","2026-05-06",{"date":206,"type":32},"2026-05-13",{"date":208,"type":32},"2025-10-10",{"date":210,"type":21},"2026-10-10",{"name":212,"class":39},"University of Minnesota",{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":17,"minAge":220,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":231,"leadSponsor":233,"locationsCount":4},"100640798","early-screening-for-cardiac-amyloid-using-a-history-of-bilateral-carpal-tunnel-syndrome-100640798","NCT07580872","Early Screening for Cardiac Amyloid Using a History of Bilateral Carpal Tunnel Syndrome","Investigations in Early Screening for Cardiac Amyloid Through History of Bilateral Carpal Tunnel Syndrome","Inclusion Criteria:\n\n* Patients aged 55 and older at the time of surgery.\n* Patients who have had bilateral carpal tunnel release surgery (i.e., at least two carpal tunnel release surgeries, one for each hand).\n* Patients who underwent surgery between the years 2010-2015.\n\nExclusion Criteria:\n\n* Patients under the age of 55 at time of surgery.\n* Patients who had unilateral carpal tunnel release surgery or surgery on only one hand.\n* Patients known alternative neurologic diagnosis explaining CTS\n* Patients with incomplete medical records\n* Patient denies PYP scan\n* Previously diagnosed amyloidosis through previous positive PYP, medical notes or self-reported\n* Patients with prior negative amyloid work up\n* Cognitive\u002Fcommunication issues without available translation support","55 Years",{"count":222,"type":21},139,[24],"Cardiac amyloidosis is a condition where abnormal protein deposits build up in the heart, making it stiff and causing it to work less effectively. One common type is caused by a normal blood protein called transthyretin (TTR), which can become unstable and form these deposits. When this happens, it is called ATTR-CM, a form of heart disease caused by TTR protein buildup. This can lead to symptoms like tiredness, shortness of breath, or swelling.\n\nBilateral carpal tunnel syndrome (CTS) is recognized as an early clinical sign of systemic amyloidosis, especially in the context of TTR amyloidosis, where amyloid deposits accumulate in the median nerve. Early identification of cardiac amyloidosis, particularly in patients with bilateral CTS, may allow for earlier intervention with disease-modifying therapies, such as tafamidis, which has been shown to improve survival and reduce hospitalizations in patients with cardiac amyloidosis.\n\nThe purpose of this study is to identify patients to evaluate them for previously undiagnosed cardiac amyloidosis. The collected information will help estimate the prevalence of cardiac amyloidosis among participants with prior bilateral CTS using a PYP nuclear scan (technetium-99m pyrophosphate scan). A PYP scan is a special heart imaging test that helps doctors see if certain abnormal proteins are building up in the heart. It's mainly used to help diagnose cardiac amyloidosis.",[226,27],"Bilateral Carpal Tunnel Syndrome (Diagnosis)","2026-05-05",{"date":229,"type":32},"2026-05-12",{"date":34,"type":21},{"date":232,"type":21},"2028-01",{"name":234,"class":39},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":17,"minAge":242,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":245,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":40},"100636578","early-detection-of-concealed-cardiac-amyloidosis-using-ai-ecg-and-ct-derived-extracellular-volume-in-patients-with-atrial-fibrillation-100636578","NCT07567508","Early Detection of Concealed Cardiac Amyloidosis Using AI-ECG and CT-Derived Extracellular Volume in Patients With Atrial Fibrillation","SEARCH-AF","Inclusion Criteria:\n\n* Adults aged 19 or older who have provided voluntary written informed consent.\n* Patients with a history of AF (paroxysmal or persistent) and one or more red-flag symptoms\u002Fsigns.\n* Patients who can undergo at least one of the following: AI-ECG analysis or CT-ECV analysis.\n\nExclusion Criteria:\n\n* Patients previously diagnosed with cardiac amyloidosis (AL or ATTR).\n* Patients with severe heart failure (NYHA class IV) or terminal illness with a life expectancy of less than 1 year.\n* Patients deemed inappropriate for participation by the investigator.","19 Years",{"count":244,"type":21},500,[24],"This study investigates the clinical efficacy of a non-invasive screening protocol using AI-ECG and CT-ECV analysis for cardiac amyloidosis. The study targets on atrial fibrillation(AF) patients with \"red-flag\" indicators.\n\nParticipants are randomized 1:1 into either an early screening or usual care group.\n\n* Early screening group : AI- ECG and\u002For CT-ECV analysis + AF treatment\n* Usual care group : AF treatment Both groups followed for 2 years to compare CA detection rates and clinical outcomes.",[248,27],"Atrial Fibrillation (AF)",[250,251,252,253],"AI-ECG","Amyloidosis","Cardiac amyloidosis","Atrial Fibrillation","2026-04-28",{"date":227,"type":32},{"date":257,"type":21},"2026-05",{"date":259,"type":21},"2029-12-31",{"name":261,"class":39},"Samsung Medical Center",{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":272,"conditions":273,"keywords":274,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":284,"leadSponsor":286,"locationsCount":40},"100636024","phase-3-64cufbp8-pet-for-early-detection-of-intracardiac-thrombus-in-amyloid-cardiomyopathy-100636024","NCT07560306","[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy","Inclusion Criteria:\n\n* Have the ability to give written informed consent;\n* History of amyloid cardiomyopathy (ATTR-CM or AL-CM);\n* History of AF or AFL;\n* Retrospective enrollment: TEE to evaluate LAA within the previous 14 days, provided the anticoagulation regimen the patient is on is not changed after the TEE. If a patient has a negative TEE and continues the same stable anticoagulation regimen, then it is unlikely that a new thrombus will develop in the LAA within the next 14 days. Likewise, if a patient not taking any anticoagulation has a thrombus in the LAA, then it is unlikely that this thrombus will resolve spontaneously in the next 14 days if the patient remains off anticoagulation. If the TEE leads to a change being made in the anticoagulation regimen (started\u002Fstopped\u002Fdose modified), then a time window of 72 hours from the TEE to PET\u002FMR imaging will be used. This scheme will ensure that the TEE can serve as an accurate gold standard;\n* Prospective: TEE to evaluate LAA thrombus scheduled in upcoming 14 days;\n\nExclusion Criteria:\n\n* Electrical implants such as cardiac pacemaker\u002Fdefibrillator, perfusion pump, direct brain stimulator;\n* Pregnancy or breastfeeding (a negative quantitative serum or urine hCG pregnancy test is required for females having child-bearing potential before the subject can participate);\n* Claustrophobia;\n* Subjects will be excluded if research-related radiation exposure exceeds current Radiology Department guidelines (i.e. 50 mSv in the prior 12 months);\n* Unable to lie comfortably on a bed inside the PET\u002FMR scanner;\n* Subjects under direct or indirect (i.e., same department as PIs) supervision of the principal investigator;\n* Body weight over the weight limit for the moving table (\\> 300 lbs for the MR table);\n* Metallic or electric implants contraindicated for PET\u002FMR scanning;\n* Stroke, myocardial infarction, cardiac or major surgery within the last 3 months;\n* History of LAA ligation\u002Fexclusion or presence of a LAA occlusion device;\n* History of syncope within the last 6 weeks;\n* Heart rate persistently \\>120 bpm or persistently \\\u003C50 bpm;\n* Daytime pauses \\>3 seconds;\n* Lack of a prior transthoracic echocardiogram within the previous 6 months;\n* Does not have the ability to give written informed consent;\n* Determined by the investigator(s) to be clinically unsuitable for the study (e.g., based on screening visit and\u002For during study procedures);",{"count":269,"type":21},20,[271],"PHASE3","The primary goal of this pilot study is to determine whether \\[64Cu\\]FBP8, a novel fibrin-binding positron emission tomography (PET) probe, can identify intracardiac thrombi when paired with simultaneous hybrid cardiac PET\u002FMRI in twenty (20) individuals with transthyretin or light chain cardiac amyloidosis and atrial fibrillation (AF) or atrial flutter (AF).\n\nThe primary hypothesis of this study is that \\[64Cu\\]FBP8 PET\u002FMRI can identify intracardiac thrombi in \\>90% of subjects with confirmed intracardiac thrombi based on transesophageal echocardiogram (TEE). In secondary analyses, the investigators will seek to determine associations between intracardiac thrombi and left atrial function and left ventricular amyloid burden.",[27],[251,275,276,277,278,279],"Cardiac","Heart","Imaging","Diagnosis","Thrombosis","2026-04-24",{"date":282,"type":32},"2026-05-01",{"date":282,"type":21},{"date":285,"type":21},"2027-03-30",{"name":287,"class":39},"Brigham and Women's Hospital",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":40},"100616676","a-study-of-deep-learning-for-echo-analysis-tracking-and-evaluation-100616676","NCT07308704","A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation","DELINEATE-Deploy: Deep Learning for Echo Analysis, Tracking, and Evaluation - Prospective Deployment Platform IRB","Inclusion criteria:\n\n* Genetic cardiomyopathy arm: Clinicians who order, perform, and interpret echocardiograms and act on echocardiogram results, including both physicians and allied health staff taking care of patients aged ≥18 years who are undergoing a comprehensive TTE at a participating Mayo Clinic site with AI-Echo analysis indicating high risk for a genetic cardiomyopathy. A high-risk score will be defined by a specific threshold determined in model development to maximize sensitivity while maintaining an adequate positive predictive value to support clinical deployment\n* Ischemic cardiomyopathy arm: Clinicians who order, perform, and interpret echocardiograms and act on echocardiogram results, including both physicians and allied health staff taking care of patients aged ≥18 years who are undergoing a comprehensive TTE with AI-Echo analysis indicating high risk for ischemic cardiomyopathy. A high-risk score will be defined by a specific threshold determined in model development to maximize sensitivity while maintaining an adequate positive predictive value to support clinical deployment.\n* Cardiac amyloidosis arm: Clinicians who order, perform, and interpret echocardiograms and act on echocardiogram results, including both physicians and allied health staff taking care of patients aged ≥18 years who are undergoing a comprehensive TTE with AI-Echo analysis indicating high risk for cardiac amyloidosis. A high-risk score will be defined by a specific threshold determined in model development to maximize sensitivity while maintaining an adequate positive predictive value to support clinical deployment.\n* Hypertrophic cardiomyopathy (HCM) arm: Clinicians who order, perform, and interpret echocardiograms and act on echocardiogram results, including both physicians and allied health staff caring for patients aged ≥18 years who are undergoing a comprehensive TTE at a participating Mayo Clinic site, with AI-Echo analysis indicating high risk for HCM. A high-risk score will be defined by a specific threshold determined during model development to maximize sensitivity while maintaining adequate positive predictive value for clinical deployment.\n\nExclusion criteria:\n\n* Genetic cardiomyopathy arm: Studies performed within the past 2 years at a Mayo site or in those patients with known or suspected diagnosis of genetic cardiomyopathy under evaluation, on hospice care, or who have an expected non-cardiac life expectancy \\\u003C1 year, and patients who have opted out of institutional and state research authorizations.\n* Ischemic cardiomyopathy arm: Studies performed within the past 2 years at a Mayo site or in those patients with known CAD; prior myocardial infarction; revascularization with PCI or CABG; ischemic testing within the past 12 months; hospice care or expected non-cardiac life expectancy \\\u003C1 year, and patients who have opted out of institutional and state research authorizations.\n* Cardiac amyloidosis arm: Studies performed within the past 2 years at a Mayo site or in those patients with prior amyloid-specific testing (e.g., technetium pyrophosphate scan, cardiac MRI with late gadolinium enhancement suggestive of amyloid) or biopsy-proven systemic amyloidosis, on hospice care, or have expected non-cardiac life expectancy \\\u003C1 year, and patients who have opted out of institutional and state research authorizations.\n* Hypertrophic cardiomyopathy (HCM) arm: Studies performed within the past 2 years at a Mayo site or patients with a known diagnosis of HCM documented in the medical record prior to the index TTE, prior septal reduction therapy (surgical myectomy or alcohol septal ablation), or patients on hospice care or with an expected non-cardiac life expectancy \\\u003C1 year, and patients who have opted out of institutional and state research authorizations.",{"count":296,"type":21},10040000,"The purpose of this study is to deploy and evaluate informational AI-Echo algorithms that assist echo clinicians in interpreting core echocardiographic parameters (e.g., LV\u002FRV size and function, valvular disease severity) and stratifying disease progression risk. The primary outcome is clinician usability, interpretive consistency, and workflow integration. Second, we will conduct a pragmatic, stepped-wedge clinical trial with multiple arms evaluating diagnostic AI-Echo algorithms designed to identify specific cardiovascular diseases- such as genetic cardiomyopathy, ischemic heart disease, and cardiac amyloidosis-and assess whether AI deployment increases diagnostic testing and shortens time to diagnosis. Trials will be conducted using EHR-based notification systems with cluster-level randomization.",[299,300,27],"Cardiomyopathy","Ischemic Heart Disease","2026-04-15",{"date":303,"type":32},"2026-04-16",{"date":305,"type":32},"2026-02-26",{"date":307,"type":21},"2028-02",{"name":309,"class":39},"Mayo Clinic",{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":17,"minAge":317,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":320,"conditions":321,"keywords":322,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":5},"100548923","cardiac-amyloidosis-prevalence-of-in-older-subjects-affected-by-heart-failure-100548923","NCT06427304","Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure","ARNOLD","Inclusion Criteria:\n\n* Aged ≥ 80 years\n* Hospitalised for decompensation of heart failure in the last 12 months\n* Subjects with hypertrophy of the septum or left ventricle at cardiac echography (defined as ≥ 12 mm)\n* Subjects able to undergo a bone scintigraphy scan\n* Subjects willing to participate\n\nExclusion Criteria:\n\n* Subjects refusing to participate\n* Subjects admitted to palliative care unit.\n* Subjects under guardianship\n* Subjects with a definite diagnosis of cardiac amyloidosis","80 Years",{"count":319,"type":21},637,"Tne aim purpose of this observational, multicentre and propective study is to determine the prevalence of cardiac amyloidosis in geriatric patients aged 80 years and older hospitalized within the last 12 months for heart failure with left ventricular hypertrophy (septum ≥ 12 mm) on echocardiography",[27],[252,323,324],"Heart failure with left ventricular hypertrophy","Positive bone scintigraphy",{"date":326,"type":32},"2026-04-20",{"date":328,"type":32},"2024-07-01",{"date":330,"type":21},"2028-02-02",{"name":332,"class":39},"Gérond'if",{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":342,"conditions":343,"keywords":345,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":358},"100634348","pet-imaging-study-using-evuzamitide-to-detect-cardiac-amyloidosis-in-patients-with-inconclusive-nuclear-scans-and-elevated-tad1-levels-100634348","NCT07538518","PET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 Levels","TAD1 Risk Assessment for Cardiac Amyloidosis With Evuzamitide (TRACE)","TRACE","Inclusion Criteria:\n\n1. Diagnosed as having heart failure or TTR variant allele carriers without symptoms of heart failure.\n2. Non-diagnostic nuclear scintigraphy for ATTR-CA (Perugini Grade 0 or 1).\n3. Elevated levels of Transthyretin Amyloid Detector-1 (TAD1).\n4. No evidence of monoclonal proteins by assessment of serum kappa and lambda free light chain ratio and immunofixation of serum and urine.\n5. Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements.\n6. Able to understand and sign the informed consent document after the nature of the study has been fully explained.\n\nExclusion Criteria:\n\n1. Primary amyloidosis (AL) or secondary amyloidosis (AA).\n2. Ventricular assist device.\n3. Disabling dementia or other mental or behavioral disease.\n4. Enrollment in a clinical trial not approved for co-enrollment.\n5. Continuous intravenous inotropic therapy.\n6. Inability or unwillingness to comply with the study requirements.\n7. Chronic kidney disease requiring hemodialysis or peritoneal dialysis.\n8. Patients taking heparin, or heparin derivatives (e.g. low molecular weight heparins) for anticoagulation.\n9. Other reason that would make the subject inappropriate for entry into this study.\n10. Pregnancy or current lactational feeding of infants.",{"count":7,"type":21},"The goal of this study is to learn whether PET-CT imaging using evuzamitide can help diagnose transthyretin cardiac amyloidosis (ATTR-CA) in patients whose standard nuclear imaging results are unclear but who have elevated TAD1 levels in their blood. The main question it aims to answer is:\n\nCan evuzamitide PET-CT imaging detect signs of cardiac amyloidosis in patients with non-diagnostic nuclear scintigraphy but elevated TAD1 levels? Participants who meet eligibility criteria will receive a single PET-CT scan with evuzamitide and will be followed for approximately 28 days to monitor safety and collect additional clinical information.",[344,27],"Amyloidogenic Transthyretin (ATTR) Amyloidosis",[346,82,347,348,349],"transthyretin","TAD1","nuclear scintigraphy","Evuzamitide","2026-04-13",{"date":326,"type":32},{"date":353,"type":21},"2026-06-01",{"date":355,"type":21},"2028-04-01",{"name":357,"class":39},"Lorena Saelices",3,{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":366,"minAge":367,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":370,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":40},"100626402","chest-ca-study-of-chest-pain-and-hidden-cardiac-amyloidosis-100626402","NCT07435168","CHEST-CA: Study of Chest Pain and Hidden Cardiac Amyloidosis","CHEST-CA","Inclusion Criteria:\n\nNo signs of CAD through Rb-PET and\u002For CT coronary arteriogram\n\nExclusion Criteria:\n\nPrevious history of amyloidosis","MALE","65 Years",{"count":369,"type":21},300,[24],"The objective of this observational, prospective study is to determine the prevalence of Cardiac Amyloidosis (CA) in males over the age of 65 who experience chest pain but show no signs of coronary artery disease (CAD).\n\nPrior to inclusion, all patients will have undergone a CT coronary angiogram or an Rb-PET scan to rule out the possibility of CAD.\n\nParticipants will be subject to several examinations, including blood tests, urine samples, ECG, echocardiography, and bone scintigraphy. An endomyocardial biopsy may be conducted if necessary.",[27,373],"Chest Pain","2026-02-25",{"date":376,"type":32},"2026-02-27",{"date":378,"type":32},"2024-04-01",{"date":380,"type":21},"2027-04-01",{"name":382,"class":39},"Rigshospitalet, Denmark",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":22,"phases":393,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":405},"100624703","increased-pacemaker-lower-rate-in-attr-cardiac-amyloidosis-100624703","NCT07413081","Increased Pacemaker Lower Rate in ATTR Cardiac Amyloidosis","Increased Pacemaker Lower Rate in ATTR Cardiac Amyloidosis: a Randomized, Crossover Clinical Trial (PACE-ATTR)","PACE-ATTR","Inclusion Criteria:\n\n* ATTR-CM defined as one of the following:\n* a.Positive cardiac biopsy for ATTR amyloidosis\n* b.Positive extra-cardiac biopsy for ATTR amyloidosis AND cardiac involvement demonstrated by CMR or echocardiography\n* c.Grade 2-3 uptake on DPD-scintigraphy AND negative serum free light chain and negative urine and serum immunofixation AND cardiac involvement demonstrated by CMR or echocardiography\n* Ongoing treatment with a transthyretin stabilizer or silencer OR considered not to be a candidate for these therapies with no planned initiation during the study period.\n* NYHA functional class II-III\n* Pre-existing pacemaker and either:\n* a.Atrial pacing with minimal RV pacing (\\\u003C2%), or\n* b.His bundle or left bundle branch area pacing, or\n* c.Biventricular pacing, or\n* d.Ongoing RV pacing with a high degree of RV pace (\\>80%)\n* NT-proBNP \\>600 ng\u002FL\n* Age ≥18 years\n* Ability and willingness to provide written informed consent\n* Pacing \\>80% with a programmed lower rate of 60 (AAI\u002FCSP\u002FCRT\u002FRV-pace)\n\nExclusion Criteria:\n\n* Inability to perform the 6-minute walk test.\n* Planned coronary revascularization, ablation of atrial flutter\u002Ffibrillation, or any severe (obstructive or regurgitant) valvular heart disease expected to require intervention during the trial in the investigator's opinion.\n* MI, unstable angina, coronary revascularization (percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)), ablation of atrial flutter\u002Ffibrillation, cardioversion, valve repair\u002Freplacement, hospitalization for decompensated heart failure or cardiac resynchronisation therapy within 12 weeks prior to enrollment.\n* Planned upgrade to CRT or conduction system pacing in patients with RV pacing.\n* More than moderate valvular stenosis or regurgitation\n* Inability of the patient, in the opinion of the investigator, to understand and\u002For comply with procedures and\u002For follow-up OR any conditions that, in the opinion of the investigator, may render the patient unable to complete the study\n* Presence of any other disease than heart failure with a life expectancy of \\\u003C 1year in the investigators opinion\n* Enrollment in other interventional device or drug trials during the study period, with the exception of open label extension studies\n* Listed for cardiac transplantation\n* Initiation of SGLT2-inhibitor or mineralocorticoid receptor antagonist within 4 weeks prior to enrollment\n* Initiation or change in loop diuretic therapy within 4 weeks prior to enrollment",{"count":392,"type":21},34,[24],"In cardiac amyloidosis, the heart muscle becomes thick and stiff, making it difficult to pump enough blood with each beat. The heart also often cannot increase its stroke volume, making patients with cardiac amyloidosis more dependent on having an adequate heart rate. Many develop conduction problems and need a pacemaker. In a related condition, heart failure with preserved ejection fraction, setting a higher pacemaker rate improved patients' quality of life. It is not known if the same benefits apply to amyloidosis. This study will test whether raising the pacemaker rate improves well-being and daily function in affected patients.",[27,203],"2026-02-09",{"date":398,"type":32},"2026-02-17",{"date":400,"type":21},"2026-02-01",{"date":402,"type":21},"2027-12-31",{"name":404,"class":39},"Region Skane",9,{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":99,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":413,"targetDuration":415,"studyType":103,"phases":4,"briefSummary":416,"conditions":417,"keywords":424,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":40},"100618805","precision-diagnosis-and-risk-stratification-of-rare-cardiomyopathies-based-on-novel-cardiac-magnetic-resonance-techniques-100618805","NCT07336394","Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques","Multimodality Imaging (Cardiovascular Magnetic Resonance Imaging, Echocardiography, and Nuclear Medicine Imaging) in the Screening, Diagnosis and Risk Stratification of Rare Cardiomyopathies - a Multicenter Study","Inclusion Criteria:\n\n* Patients who have received a cardiac magnetic resonance examination since 2010 and have a suspicion of rare cardiomyopathy.\n\nExclusion Criteria:\n\n* Severe arrhythmia;\n* Severe primary cardiac valvular disease;\n* Refuse to participate in the study.",{"count":414,"type":21},1000,"10 Years","What is this study about? This research is focused on improving the care for people with rare heart muscle diseases, known as rare cardiomyopathies. These are uncommon conditions where the heart muscle becomes stiff, thick, or enlarged, making it harder for the heart to pump blood. Because they are rare, they can be difficult to diagnose and manage.\n\nThe investigators are testing new, advanced ways of using a heart scan called a Cardiac Magnetic Resonance (CMR). Participants can think of a CMR as a very powerful camera that takes detailed pictures of their heart without using radiation.\n\nWhat is the study trying to learn? Better Diagnosis: The investigators want to see if these new scanning techniques can help us identify these rare heart conditions more clearly and accurately. This means patients could get a correct diagnosis sooner.\n\nPersonalized Risk Assessment: The investigators want to see if the scan can help us understand the future risk for each patient better. For example, can it help predict which patients are more likely to have a heart rhythm problem or need specific treatments? This helps doctors create a care plan that is tailored just for participants.\n\nWhat does this mean for participants? If participants choose to take part, they will undergo a CMR scan that uses these new techniques. By participating, they will be helping us find better ways to diagnose and care for people with their condition in the future. The goal is to turn uncertainty into clearer, more personalized information for patients and families.",[418,419,27,420,421,422,423],"Danon Disease","Fabry Disease","Noonan Syndrome","Cardiac Sarcoidosis","Glycogen Storage Disease","Idiopathic Cardiomyopathy",[425,426,427,428,429,80],"cardiovascular magnetic resonance imaging","early diagnosis","prognosis","rare cardiomyopathies","nuclear medicine imaging","2026-01-19",{"date":432,"type":32},"2026-01-21",{"date":434,"type":32},"2010-01-01",{"date":436,"type":21},"2030-12-30",{"name":438,"class":39},"Chinese Academy of Medical Sciences, Fuwai Hospital",{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":22,"phases":448,"briefSummary":449,"conditions":450,"keywords":451,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":40},"100531236","amylo-shiatsu-acute-chronic-effects-of-shiatsu-on-symptoms-and-quality-of-life-of-amyloidosis-patients-100531236","NCT06197165","Amylo-Shiatsu-Acute-Chronic: Effects of Shiatsu on Symptoms and Quality of Life of Amyloidosis Patients","AMYLO-SHIATSU","Inclusion Criteria:\n\n* Age ≥ 18 years ;\n* Patient with :\n\n  * Transthyretin of genetic origin (TTR) ;\n  * Transthyretin of non-mutated origin (WT) ;\n  * Light Chain (AL);\n* Membership of a social security scheme, beneficiary or beneficiary's beneficiary (excluding AME);\n* Written patient consent.\n* Score greater than or equal to 3 on the EESE-R questionnaire (Edmonton Symptom Evaluation Scale-Revised), for at least 1 symptom among: dyspnea, digestive disorders, nausea, pain, anxiety, depression (Shiatsu and non-Shiatsu groups);\n* Score global à l'EESE-R supérieur ou égal à 10 (groupes Shiatsu et sans shiatsu).\n\nExclusion Criteria:\n\n* Patients with orthostatic hypotension;\n* Patients with bullous amyloidosis (fragile skin);\n* Patients who have already received Shiatsu treatment;\n* Patient with insufficient autonomy to maintain sitting position;\n* Patient with insufficient autonomy to move from home to hospital;\n* Participating in another interventional study, or within the exclusion period of a previous study, if applicable;\n* Known pregnancy or breast-feeding;\n* Patient under known guardianship at the time of inclusion;\n* Patient under AME.",{"count":447,"type":21},108,[24],"The objective of this study is to assess the beneficial effects of three targeted Shiatsu sessions compared to \"comfort\" Shiatsu on symptoms in patients with severe cardiac amyloidosis. Specifically, the study aims to evaluate the short-term impact of a targeted Shiatsu session on neuro-cardiovascular physiological parameters and symptoms in patients with cardiac amyloidosis, in comparison to comfort Shiatsu and no Shiatsu. Additionally, the study will investigate the effects of three targeted Shiatsu sessions versus \"comfort\" Shiatsu and no Shiatsu on various symptoms (fatigue, sleep disturbances, pain, anxiety, depression, dyspnea, digestive disorders, nausea) and quality of life in cardiac amyloidosis patients with severe symptoms. Patient satisfaction with Shiatsu will also be evaluated, alongside an assessment of the tolerance to Shiatsu.",[27],[452],"Cardiac amyloidosis - Targeted Shiatsu - pain","2026-01-14",{"date":455,"type":32},"2026-01-15",{"date":457,"type":32},"2024-03-12",{"date":459,"type":21},"2026-04-12",{"name":461,"class":39},"Assistance Publique - Hôpitaux de Paris",{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":99,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":469,"targetDuration":470,"studyType":103,"phases":4,"briefSummary":471,"conditions":472,"keywords":475,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":144},"100610813","18fft8-pet-imaging-in-immunoglobulin-light-chain-amyloidosis-100610813","NCT07232459","[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis","Clinical Study of [18F]FT8 PET\u002FCT in Evaluating Amyloidosis","1. Subject Recruitment Participants will be recruited from outpatients and\u002For inpatient populations of the Hematology Department at Tianjin Medical University General Hospital. The principal investigator and collaborating hematologists will ensure consistent application of diagnosis and enrollment criteria based on standardized guidelines. The planned enrollment includes 20 patients with systemic amyloidosis (including cardiac involvement) and 5 healthy volunteers.\n2. Amyloidosis Patients:\n\n2.1 Inclusion Criteria:\n\nSubjects must meet all of the following criteria:\n\n1. Adult patients (age ≥ 18 years);\n2. Suspected, newly diagnosed, or previously diagnosed with cardiac amyloidosis, with supporting evidence from one or more of the following: cardiac MRI, contrast-enhanced CT, serum biomarkers (e.g., NT-proBNP, Troponin), or histopathological confirmation of amyloidosis.\n3. Scheduled to undergo a clinical Pan-Amyloid PET\u002FCT scan as part of standard care or clinical evaluation.\n4. Able to understand the study procedures and provide written informed consent. 2.2 Exclusion Criteria\n\nSubjects will be excluded based on any of the following:\n\n1. Confirmed non-cardiac amyloidosis or other non-amyloid cardiac pathologies that could confound image interpretation.\n2. Pregnancy or breastfeeding.\n3. Any medical, psychological, or social condition that, in the opinion of the investigator, would compromise the subject's ability to participate fully or complete the study follow-up.\n\n3\\. Healthy Volunteers: 3.1 Inclusion Criteria:\n\nSubjects must meet all of the following criteria:\n\n1. Adult subjects (age ≥ 18 years);\n2. No clinical evidence of active cardiac or systemic disease, as confirmed by medical history review, physical examination, and electrocardiogram (ECG).\n3. Able to understand the study procedures and provide written informed consent. 3.2 Exclusion Criteria:\n\nSubjects will be excluded based on any of the following:\n\n1. History or current diagnosis of any significant cardiac, hepatic, renal, or neurological disorder.\n2. Pregnancy or breastfeeding.\n3. Any condition that, in the opinion of the investigator, could pose an increased risk from the study procedure or interfere with the interpretation of study data.",{"count":7,"type":21},"7 Days","\\[18F\\]FT8, a derivative of 1-(4-pyridyl)-4-piperazinyl arene (\\[18F\\]TPZA), exhibits high affinity for AL amyloid in myocardial tissue sections and shows no significant binding to transthyretin amyloid. By comparing its diagnostic performance against established clinical methods, including echocardiography, contrast-enhanced MRI, and relevant laboratory tests, this study aims to establish \\[18F\\]FT8 as the basis for a robust PET protocol for the direct visualization and differential diagnosis of AL amyloidosis . The study preimarily evaluates the safety and diagnostic efficacy of \\[18F\\]FT8 PET imaging in human subjects.",[473,27,251,474],"Amyloid","Healthy Subjects",[476,252,477],"PET\u002FCT","immunoglobulin light chain","2025-11-15",{"date":480,"type":32},"2025-11-18",{"date":482,"type":32},"2025-07-21",{"date":484,"type":21},"2028-12-20",{"name":486,"class":39},"Tianjin Medical University",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":99,"sex":17,"minAge":495,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":498,"conditions":499,"keywords":503,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":514,"locationsCount":358},"100609525","us-benchmarking-clinical-study-100609525","NCT07215715","US Benchmarking Clinical Study","Myocardial & Hepatic Shear Wave Velocity Measurements in Patients With Non-Reduced-Ejection Fraction Heart Failure and Control Subjects - US Benchmarking Clinical Study","EMS-CT-1","Inclusion Criteria:\n\nInclusion Criteria Common to all three Study Arms:\n\n1. Male or female age ≥ 60 years\n2. Signed informed consent and able to comply with protocol\n\n   Inclusion Criteria Common to the Heart Failure with non-reduced left ventricular ejection fraction (LVEF) with or without transthyretin amyloid cardiomyopathy (ATTR-CM) Arms:\n3. Patients meeting the Universal Definition of Heart Failure \\& HeartShare study criteria.\n4. LVEF \\>40% on the last available imaging study\n5. Left ventricular hypertrophy (LVH) defined as left ventricular mass index (mass\u002FBSA) in female \\> 95 g\u002Fm², in male \\> 115 g\u002Fm² according to American Society of Echocardiography\u002FEuropean Association of Cariology (ASE\u002FEAC) guidelines42 OR as interventricular septum (IVS) thickness ≥12 mm\n\n   Inclusion criterion specific to HF with non-reduced LVEF without ATTR-CM Arm:\n6. Negative (grade 0) Pyrophosphate (PYP) scintigraphy within 24 months prior to the enrolment in the study OR Simple Score \\\u003C643 OR negative endomyocardial biopsy\n\n   Inclusion criterion specific to HF with non-reduced LVEF with ATTR-CM Arm:\n7. ATTR-CM objectively confirmed and classified at any time prior to the enrollment in the study, with monoclonal protein AL amyloidosis ruled out, according to American Heart Association (AHA) 2020 criteria\n\n   Inclusion criteria in Control Subjects:\n8. No diagnosis of HF or cardiomyopathy according to the universal definition of Heart Failure\n9. No diagnosis of Transthyretin amyloid cardiomyopathy (ATTR-CM) or Amyloid light-chain (AL) amyloidosis\n\nExclusion Criteria:\n\nExclusion criteria common to the three arms:\n\n1. Pregnant OR pre-menopausal woman\n2. Vulnerable patients\n3. Acute Coronary Syndrome within 30 days\n4. Heart rate greater than 130 beats\u002Fminute at the time of the measurements\n5. Atrial fibrillation or flutter at the time of SWV measurement (history of AF is authorized provided they patient is in sinus rhythm at the time of the measurements)\n6. Any clinically significant cardiac arrhythmia at the time of SWV measurement\n7. Poor echogenicity preventing accurate ultrasound measurements\n8. Patients with segmental wall motion abnormalities thought to be due to myocardial infarction.\n9. Severe mitral or aortic valve disease (regurgitation or stenosis) excluded if the cause is other than ATTR (e.g., prolapse, endocarditis, prosthetic valve.)\n10. Severe tricuspid valve disease (regurgitation or stenosis) excluded if the causes are other than ATTR.\n11. Distance from skin to IVS ≥ 8 cm\n12. Any prosthetic mechanical valve\n13. Patients with mechanical cardiac assist devices other than pacemakers or defibrillators\n14. Heart, lung, liver or kidney transplant history or expected in the next year\n15. Severe renal impairment with eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m² or end-stage renal disease or patient on dialysis.\n16. Presence of any competing life-threatening risk over the next 12 months\n17. Complicated uncontrolled diabetes mellitus HbA1c ≥9% with target organ damage.\n18. Uncontrolled and persistent high-blood pressure with diastolic pressure \\> 100 mmHg or systolic pressure \\> 160 mmHg at the time of the measurement.\n19. Acute decompensated state such as volume overload, etc. in the opinion of the study investigator\n20. Skin abnormalities, infections, or open wounds at the site of the SVW measurement\n21. Liver disease, at least moderate\n\n    Exclusion criteria in both the HF with non-reduced LVEF with or without ATTR-CM Arms:\n22. Known inherited cardiomyopathy, infiltrative cardiomyopathy (other than ATTR-CM for the study arm for ATTR-CM), cardiomyopathy from muscular dystrophies, cardiomyopathy with reversible causes (e.g., stress cardiomyopathy), hypertrophic cardiomyopathy or known pericardial constriction\n23. History of treatment for ATTR-CM with Transthyretin (TTR) depleters\n\n    Exclusion criteria Specific to Control Subjects:\n24. Any diagnosis of cardiomyopathy or HF, whatever the cause46\n25. LVH based on LV mass index female \\>95 g\u002Fm², in male ≥115 g\u002Fm² OR IVS thickness ≥12 mm unless thought to be due to athlete's heart","60 Years",{"count":497,"type":21},150,"The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failure and left ventricular hypertrophy, with or without transthyretin amyloidosis with cardiomyopathy (ATTR-CM), and in control subjects without heart failure or cardiomyopathy.\n\nThe main question it aims to answer is:\n\n• Can SWV be used to measure myocardial and liver stiffness in the study's target populations? Researchers will compare patients with ATTR-CM, patients without ATTR-CM, and a control group to determine the distributions of SWV in each population.\n\nParticipants will:\n\n* Have a standard cardiology assessment, including a physical exam, blood work, and an echocardiogram.\n* Undergo an investigational assessment with the eMyosound LYRA device to measure SWV in their myocardium and liver.\n* Have the investigational assessment repeated by a second observer to assess measurement reliability.",[500,501,502,77,27],"HFpEF - Heart Failure With Preserved Ejection Fraction","HFmrEF","ATTR-CM (Transthyretin Amyloid Cardiomyopathy)",[504,505,491,506,27,507],"Shear Wave Velocity","non-invasive ultrasound elastography","Heart Failure","ATTR-CM","2025-10-16",{"date":510,"type":32},"2025-10-20",{"date":512,"type":32},"2025-09-16",{"date":34,"type":21},{"name":515,"class":62},"eMyosound SAS",{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":17,"minAge":129,"maxAge":4,"enrollmentInfo":523,"targetDuration":524,"studyType":103,"phases":4,"briefSummary":525,"conditions":526,"keywords":527,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":40},"100604812","hybrid-florbetaben-petmri-for-imaging-of-cardiac-amyloidosis-100604812","NCT07154381","Hybrid Florbetaben PET\u002FMRI for Imaging of Cardiac Amyloidosis","Monocentric Observational Trial for Florbetaben PET\u002FMRI Hybrid Imaging in Patients With Cardiac Amyloidosis","Inclusion Criteria:\n\n* Age \\> 40 years\n* proven Amyloidosis (ATTR or AL)\n* Women: negative pregnancy test less than weeks prior imaging.\n\nExclusion Criteria:\n\n* Patients receiving amyloidosis-specific treatment prior study inclusion.\n* Patients participating in other clinical trails for treatment of Amyloidosis.\n* Pregnancy\n* Contraindiactions for MRI (eGFR\\\u003C30ml\u002Fmin\u002F1.73m2; gadolinium allergy; metallic implants or device not suited for 3T MRI).\n* inability of consent\n* Refusal of consent",{"count":7,"type":21},"36 Months","Exploration of prognostic parameters in 18F-Florbetaben PET\u002FMRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).",[27],[528,529],"PET\u002FMRI","Florbetaben","2025-08-26",{"date":532,"type":32},"2025-09-04",{"date":534,"type":32},"2019-12-09",{"date":536,"type":21},"2025-12",{"name":538,"class":39},"University Hospital, Essen",{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":547,"conditions":548,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":40},"100604813","cardiac-amyloid-deposits-and-heart-dysfunction-in-alzheimers-disease-100604813","NCT07154394","Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease","Investigation of Cardiac Amyloid Deposits as a Cause of Cardiac Dysfunction in Alzheimer's Disease (Untersuchung Von Kardialen Amyloidablagerungen Als Ursache Einer Funktionseinschränkung Des Herzens Bei Alzheimer Demenz)","Inclusion Criteria:\n\n* Patients undergoing cerebral amyloid PET examination for clinical indication to clarify Alzheimer's disease\n* No contraindications to undergo an MRI examination\n* No contraindications to undergo an Amyloid PET scan\n\nExclusion Criteria:\n\n* Patients with vascular dementia and confirmed other causes of dementia (e.g. stroke, vitamin deficiency, thyroid insufficiency, toxic causes such as alcohol)\n* Patients with pronounced cardiac preconditions\n* Pregnant and breastfeeding women",{"count":131,"type":21},"This study seeks to explore the possible common pathogenesis of both cardiac amyloidosis and Alzheimer's disease, which can both be associated with amyloid deposits. Using Positron Emission Tomography (PET) scans with amyloid tracers - a conventional tool for non-invasively imaging amyloid deposits in Alzheimer's disease - the research will extend this imaging methodology to the heart.\n\nThe study will conduct additional PET\u002FMRI scans of the heart in patients undergoing amyloid tracer PET scans for Alzheimer's evaluations. Each participant will also undergo an echocardiogram and a clinical examination of dementia.\n\nThis could potentially enhance diagnostic practices in both cardiac amyloidosis and Alzheimer's disease.",[549,550,27],"Dementia, Alzheimer Type","Mild Cognitive Impairment",{"date":532,"type":32},{"date":553,"type":32},"2022-08-15",{"date":555,"type":21},"2025-09-14",{"name":538,"class":39},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":99,"sex":17,"minAge":18,"maxAge":317,"enrollmentInfo":563,"targetDuration":470,"studyType":103,"phases":4,"briefSummary":564,"conditions":565,"keywords":566,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":144},"100602980","pan-amyloid-petct-in-various-amyloid-related-disease-100602980","NCT07130565","Pan-Amyloid PET\u002FCT in Various Amyloid-Related Disease","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated cardiac amyloidosis (supporting evidence may include MRI, CT, serum markers and pathology report); (iii) patients who had scheduled Pan-Amyloid PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-CA lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":244,"type":21},"To evaluate the potential usefulness of 18F-92\u002FAV45\u002FTPZA\u002FFT8, 11C-PIB positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various Pan-Amyloid-related disease patients.",[473,27,251],[476,567,568],"MRI","Pan-Amyloid","2025-08-12",{"date":571,"type":32},"2025-08-19",{"date":573,"type":32},"2023-11-01",{"date":575,"type":21},"2028-11-01",{"name":486,"class":39},{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":585,"targetDuration":4,"studyType":22,"phases":587,"briefSummary":588,"conditions":589,"keywords":590,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":40},"100523514","capacity-cardiac-amyloidosis-and-physical-activity-study-100523514","NCT06096675","CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study","Pilot Study Evaluating Supervised Cardiac Rehabilitation in Patients With Cardiac Amyloidosis","CAPACITY","Inclusion Criteria:\n\n* Age \\> 18\n* New York Heart Association (NYHA) Class I-III Heart Failure\n* Able to Exercise\n* On stable treatment for their cardiac amyloidosis or under active surveillance\n* Life expectancy of at least 6 months\n* Ability to understand and the willingness to sign a written informed consent document in English, and the willingness\u002Fability to comply with the protocol activities\n* Participant must be able and willing to follow the cardiac rehabilitation activities\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Inability to commit to in-person supervised exercise sessions for three one-hour sessions a week for 12 weeks\n* NYHA Class IV Heart Failure\n* Pulmonary disease requiring home oxygen\n* Gait instability or history of prior falls\n* In the opinion of the Principal Investigator, have a clinically significant comorbid disease that is likely to affect the ability of the patient to complete the trial, interfere with their ability with measurement of self-reported outcomes.",{"count":586,"type":21},50,[24],"Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.",[27],[591,592,593],"heart failure","preserved ejection fraction","cardiac rehabilitation","2025-07-25",{"date":596,"type":32},"2025-07-28",{"date":598,"type":32},"2024-01-22",{"date":600,"type":21},"2027-06",{"name":602,"class":39},"Wake Forest University Health Sciences",{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":4,"eligibilityCriteria":609,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":610,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":611,"conditions":612,"keywords":613,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":40},"100450000","artificial-intelligence-guided-echocardiographic-screening-of-rare-diseases-echonet-screening-100450000","NCT05139797","Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)","Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases","Inclusion Criteria:\n\n* Patients who have a high suspicion for cardiac amyloidosis by AI algorithm\n\nExclusion Criteria:\n\n* Patients who decline to be seen at specialty clinic\n* Patients who have passed away",{"count":369,"type":21},"Despite rapidly advancing developments in targeted therapeutics and genetic sequencing, persistent limits in the accuracy and throughput of clinical phenotyping has led to a widening gap between the potential and the actual benefits realized by precision medicine.\n\nRecent advances in machine learning and image processing techniques have shown that machine learning models can identify features unrecognized by human experts and more precisely\u002Faccurately assess common measurements made in clinical practice.\n\nThe investigators have developed an algorithm, termed EchoNet-LVH, to identify cardiac hypertrophy and identify patients who would benefit from additional screening for cardiac amyloidosis and will prospectively evaluate its accuracy in identifying patients whom would benefit from additional screening for cardiac amyloidosis.",[27],[614,615],"Echocardiogram","Artificial Intelligence","2025-06-24",{"date":618,"type":32},"2025-06-27",{"date":620,"type":32},"2021-11-18",{"date":622,"type":21},"2027-06-01",{"name":624,"class":39},"Cedars-Sinai Medical Center"]